Int'l : +1(646) 600-5072 | query@kbvresearch.com
Published Date : 20-11-2018 |
Pages: 86 |
Formats: PDF |
The Asia Pacific Market would witness market growth of 16.5% CAGR during the forecast period (2018 – 2024). Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.
Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd.
Scope of the Study
Market Segmentation:
By Technology
By Application
By End User
By Country
Companies Profiled
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Cancer Immunotherapy Market, by Technology
1.4.2 Asia Pacific Cancer Immunotherapy Market, by Application
1.4.3 Asia Pacific Cancer Immunotherapy Market, by End User
1.4.4 Asia Pacific Cancer Immunotherapy Market, by Countries
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Cancer Immunotherapy Market by Technology
3.1.1 Asia Pacific Monoclonal Antibodies Cancer Immunotherapy Market by Country
3.1.2 Asia Pacific Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
3.1.3 Asia Pacific Other Technology Cancer Immunotherapy Market by Country
Chapter 4. Asia Pacific Cancer Immunotherapy Market by Application
4.1.1 Asia Pacific Cancer Immunotherapy Lung Cancer Market by Country
4.1.2 Asia Pacific Cancer Immunotherapy Breast Cancer Market by Country
4.1.3 Asia Pacific Cancer Immunotherapy Colorectal Cancer Market by Country
4.1.4 Asia Pacific Cancer Immunotherapy Melanoma Market by Country
4.1.5 Asia Pacific Cancer Immunotherapy Prostate Cancer Market by Country
4.1.6 Asia Pacific Cancer Immunotherapy Head & Neck Cancer Market by Country
4.1.7 Asia Pacific Other Application Cancer Immunotherapy Market by Country
Chapter 5. Asia Pacific Cancer Immunotherapy Market by End User
5.1.1 Asia Pacific Hospitals Cancer Immunotherapy Market by Country
5.1.2 Asia Pacific Clinics Cancer Immunotherapy Market by Country
5.1.3 Asia Pacific Other End User Cancer Immunotherapy Market by Country
Chapter 6. Asia Pacific Cancer Immunotherapy Market by Country
6.1 China Cancer Immunotherapy Market
6.1.1 China Cancer Immunotherapy Market by Technology
6.1.2 China Cancer Immunotherapy Market by Application
6.1.3 China Cancer Immunotherapy Market by End User
6.2 Japan Cancer Immunotherapy Market
6.2.1 Japan Cancer Immunotherapy Market by Technology
6.2.2 Japan Cancer Immunotherapy Market by Application
6.2.3 Japan Cancer Immunotherapy Market by End User
6.3 India Cancer Immunotherapy Market
6.3.1 India Cancer Immunotherapy Market by Technology
6.3.2 India Cancer Immunotherapy Market by Application
6.3.3 India Cancer Immunotherapy Market by End User
6.4 South Korea Cancer Immunotherapy Market
6.4.1 South Korea Cancer Immunotherapy Market by Technology
6.4.2 South Korea Cancer Immunotherapy Market by Application
6.4.3 South Korea Cancer Immunotherapy Market by End User
6.5 Singapore Cancer Immunotherapy Market
6.5.1 Singapore Cancer Immunotherapy Market by Technology
6.5.2 Singapore Cancer Immunotherapy Market by Application
6.5.3 Singapore Cancer Immunotherapy Market by End User
6.6 Malaysia Cancer Immunotherapy Market
6.6.1 Malaysia Cancer Immunotherapy Market by Technology
6.6.2 Malaysia Cancer Immunotherapy Market by Application
6.6.3 Malaysia Cancer Immunotherapy Market by End User
6.7 Rest of Asia Pacific Cancer Immunotherapy Market
6.7.1 Rest of Asia Pacific Cancer Immunotherapy Market by Technology
6.7.2 Rest of Asia Pacific Cancer Immunotherapy Market by Application
6.7.3 Rest of Asia Pacific Cancer Immunotherapy Market by End User
Chapter 7. Company Profiles
7.1 Amgen Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental & Regional Analysis
7.1.4 Research and Development Expense
7.2 Merck & Company, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional and Segmental Analysis
7.2.4 Research & Development
7.3 Pfizer Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Revenue analysis by Region
7.3.5 Research and Development
7.4 Immunomedics Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Revenue Analysis by Region
7.4.4 Research and Development
7.5 Astrazeneca Plc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental analysis
7.5.4 Research & Development
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Revenue & Segment analysis
7.6.4 Research and Development
7.7 Eli Lilly and Company
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Bristol-Myers Squibb Company
7.9.1 Company Overview
7.1 Bayer AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
TABLE 1 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 2 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 3 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 4 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 5 ASIA PACIFIC MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 6 ASIA PACIFIC MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 7 ASIA PACIFIC CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 8 ASIA PACIFIC CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 9 ASIA PACIFIC OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 10 ASIA PACIFIC OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 11 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 12 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 13 ASIA PACIFIC CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 14 ASIA PACIFIC CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 15 ASIA PACIFIC CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 16 ASIA PACIFIC CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 17 ASIA PACIFIC CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 18 ASIA PACIFIC CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 19 ASIA PACIFIC CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 20 ASIA PACIFIC CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 21 ASIA PACIFIC CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 22 ASIA PACIFIC CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 23 ASIA PACIFIC CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 24 ASIA PACIFIC CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 25 ASIA PACIFIC OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 26 ASIA PACIFIC OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 27 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 28 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 29 ASIA PACIFIC HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 30 ASIA PACIFIC HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 31 ASIA PACIFIC CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 32 ASIA PACIFIC CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 33 ASIA PACIFIC OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 34 ASIA PACIFIC OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 35 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 36 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 37 CHINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 38 CHINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 39 CHINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 40 CHINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 41 CHINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 42 CHINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 43 CHINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 44 CHINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 45 JAPAN CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 46 JAPAN CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 47 JAPAN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 48 JAPAN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 49 JAPAN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 50 JAPAN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 51 JAPAN CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 52 JAPAN CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 53 INDIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 54 INDIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 55 INDIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 56 INDIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 57 INDIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 58 INDIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 59 INDIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 60 INDIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 61 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 62 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 63 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 64 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 65 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 66 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 67 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 68 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 69 SINGAPORE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 70 SINGAPORE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 71 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 72 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 73 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 74 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 75 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 76 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 77 MALAYSIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 78 MALAYSIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 79 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 80 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 81 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 82 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 83 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 84 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 85 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 86 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 87 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 88 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 89 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 90 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 91 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 92 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 93 KEY INFORMATION-AMGEN INC.
TABLE 94 KEY INFORMATION-MERCK & COMPANY INC.
TABLE 95 KEY INFORMATION- PFIZER INC.
TABLE 96 KEY INFORMATION- IMMUNOMEDICS INC.
TABLE 97 KEY INFORMATION- ASTRAZENECA PLC.
TABLE 98 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
TABLE 99 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 100 KEY INFORMATION – NOVARTIS AG
TABLE 101 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
TABLE 102 KEY INFORMATION – BAYER AG